Patients and Other Nonscientists Provide Valuable Input Into Medical Research Funding Decisions

Published Oct 23, 2018

New Research from Patient-Centered Outcomes Research Institute (PCORI)

Lawrenceville, NJ, USA—October 23, 2018—Value in Health, the official journal of ISPOR (the professional society for health economics and outcomes research), announced today the publication of 2 studies confirming the value of including patients and other nonscientists in the process for approving research funding. The reports, Unique Review Criteria and Patient and Stakeholder Reviewers: Analysis of PCORI’s Approach to Research Funding and Researchers, Patients, and Stakeholders Evaluating Comparative Effectiveness Research: A Mixed-Methods Study of the PCORI Reviewer Experience were published in the October 2018 issue of Value in Health. The research for the 2 papers was conducted simultaneously and led by experts from the Patient-Centered Outcomes Research Institute (PCORI). The first study was a cross-sectional analysis of administrative data from PCORI Merit Review applications across 5 funding cycles. Researchers assessed the extent to which different reviewer types influence review scores and funding outcomes, the emphasis placed on technical merit compared to other criteria by a multistakeholder panel, and the impact of the in-person discussion on agreement among different reviewer types. Results show that scientist, patient, and stakeholder (eg, clinicians, health systems administrators, policy-makers, caregivers) views all contribute to PCORI Merit Review of applications for research funding. Technical merit is critical to funding success, but patient and stakeholder ratings of other criteria also influence funding decisions. In fact, for each reviewer type, overall initial scores were changed on at least half of the applications after the in-person panel discussion. The second study used anonymous, cross-sectional surveys to understand reviewers’ perspectives of the interactions during the in-person review panel; to examine the value and challenges of including scientists, patients, and stakeholders together; and to understand the perceived importance of PCORI’s review criteria. Survey results indicate that reviewers of all types describe PCORI Merit Review as respectful, balanced, and one of reciprocal influence among different reviewer types. Challenges included concerns about a lack of technical expertise of patient/ stakeholder reviewers and about scientists dominating conversations. “PCORI was established to fund patient-centered comparative clinical effectiveness research that is relevant to patients and other healthcare decision makers and produces results that can be quickly applied in health decision making,” said author Laura Forsythe, PhD, MPH, PCORI, Washington, DC, USA. “While other funders have incorporated patients, consumers, or the public in their reviews, the extent to which PCORI involves nonscientists in application review is unprecedented. The research described in these articles provides new evidence about how the views of scientists, patients, and other stakeholders are incorporated in the PCORI Merit Review of applications for research funding, and how reviewers’ perceive the interactions involved. We hope this work will facilitate funding of research that is more relevant to healthcare decision making.” ### ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg ABOUT VALUE IN HEALTH Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2017 impact factor score is 5.494. Value in Health is ranked 3rd among 94 journals in healthcare sciences and services, 3rd among 79 journals in health policy and services, and 6th among 353 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world. Web: www.ispor.org/valueinhealth_index.asp | Twitter: www.twitter.com/ISPORJournals (@ISPORjournals)

Related Stories

ISPOR Global Panel Proposes New Structure to Improve Definitions of Digital Health Interventions

Apr 9, 2024

ISPOR—The Professional Society for Health Economics and Outcomes Research announced today the publication of a report from the ISPOR Digital Health Special Interest Group that proposes a new framework to help standardize and clarify definitions used for digital health interventions. The report, “The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report” was published in the April 2024 issue of Value in Health.

ISPOR International Panel Calls for Consensus on Medication Adherence Measures

Feb 26, 2024

ISPOR—The Professional Society for Health Economics and Outcomes Research announced the publication of a new report from the ISPOR Medication Adherence and Persistence Special Interest Group revealing significant inconsistencies in how researchers measure the effectiveness of interventions aimed at improving medication adherence. The report, “A Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions: An ISPOR Special Interest Group Report” was published in the February 2024 issue of Value in Health.

Global Experts Highlight Concerns With Implementation of IRA-Mandated Medicare Drug Price Negotiation Program

Dec 5, 2023

Value in Health announced the publication of 2 new commentaries by leading experts in health economics and outcomes research, both of which raise important questions as the Centers for Medicare & Medicaid Services move forward to implement the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×